Home › Compound Library › Cabotegravir (Apretude / Vocabria)

Cabotegravir (Apretude / Vocabria)

Antiretroviralprescriptionoral · inferred

INSTI available as 30 mg oral cabotegravir (Vocabria) and as a long-acting injection. This catalog entry models the authored 30 mg oral lead-in regimen; the 600 mg extended-release intramuscular depot requires a separate route model.

Projected serum levels — 30 mg, once daily

Cabotegravir (Apretude / Vocabria)
Cabotegravir (Apretude / Vocabria) modeled serum levels, 30 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 7 days. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 7
Cabotegravir (Apretude / Vocabria) modeled serum levels with a loading dose of 78.5 mg, then 30 mg once daily The first dose is larger so levels approach steady state faster. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 30 mg once daily (oral).

Loading schedule: 78.5 mg on day 1, then 30 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~7 days: peak ≈ 59.2 mg, trough ≈ 38.0 mg body load. Population-based estimate over 15 days for a 30 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antiretroviral
Route modeled
Oral
Model confidence
inferred
Half-life
41 h
Common dose
30 mg
Suggested maximum
30 mg/day
Reference dose range
15–30 mg (single dose)
Suggested cadence
once daily
Validated against
30 mg oral — Cmax 8 mg/L at 3 h

Documented interactions

  • danger
    Glecaprevir + Cabotegravir (Apretude / Vocabria) CYP inhibition

    Glecaprevir reversible_inhibitor of UGT1A1 predicted to change Cabotegravir (Apretude / Vocabria) AUC by ~2.17x

  • danger
    Levothyroxine (Synthroid) + Cabotegravir (Apretude / Vocabria) Protein binding

    Cabotegravir (Apretude / Vocabria) may displace Levothyroxine (Synthroid) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index;…

  • danger
    Phenobarbital + Cabotegravir (Apretude / Vocabria) CYP induction

    Phenobarbital inducer of UGT1A1 predicted to change Cabotegravir (Apretude / Vocabria) AUC by ~0.46x

  • danger
    Rifampin + Cabotegravir (Apretude / Vocabria) CYP induction

    Rifampin inducer of UGT1A1 predicted to change Cabotegravir (Apretude / Vocabria) AUC by ~0.39x

  • warning
    Apigenin + Cabotegravir (Apretude / Vocabria) Protein binding

    Apigenin may displace Cabotegravir (Apretude / Vocabria) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Aripiprazole (Abilify) + Cabotegravir (Apretude / Vocabria) Protein binding

    Aripiprazole (Abilify) may displace Cabotegravir (Apretude / Vocabria) from plasma protein binding sites, transiently raising free drug concentration.

Serum checks 172 modeled interaction pairings for cabotegravir (apretude / vocabria) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Cabotegravir for HIV prevention in cisgender men and transgender women Landovitz RJ et al. · New England Journal of Medicine, 2021 DOI

    HPTN 083 showing long-acting injectable cabotegravir superior to daily oral TDF/FTC for HIV prevention (66% fewer infections), establishing LA-PrEP.

  2. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor Spreen W et al. · HIV Clinical Trials, 2013 DOI

    First-in-human PK/PD of cabotegravir oral and IM formulations, establishing apparent half-life and feasibility of monthly-to-bimonthly dosing.

2 published studies referenced in the app, each with a plain-language summary.